SOCIETY OF INTERVENTIONAL RADIOLOGY (SIR) FOUNDATION
REQUEST FOR PROPOSALS (RFP)

Part 1. Overview Information

Participating Organization: SIR Foundation

Funding Opportunity Title: The Dr. Scott C. Goodwin Grant for Adenomyosis

Number of Applications: Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

Award Amount: Project Budget may not exceed $460,000.

Funding Opportunity Purpose: This opportunity is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development focused on a prospective and comparative adenomyosis clinical trial.

Open Date: May 1st, 2024, at 5:00 p.m. EST

Proposal Development Form Due Date: June 30th, 2024, on or before 5:00 p.m. EST

Pre-review Due Date: September 20th, 2024, on or before 5:00 p.m. EST

Final Application Due Date: January 15th, 2025 on or before 5:00 p.m. EST

Scientific Review: January 16th, 2025 – April 1st, 2025

Grant Review Study Section Review: April 2025

Earliest Project Start Date: June 1, 2025
Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

SIR and SIR Foundation believe in promoting a culture of inclusion and strengthening the specialty of interventional radiology (IR) through different perspectives.

SIR Foundation supports research in interventional radiology and benefits researchers at all levels, from graduate students to established practitioners. The emergence of interventional radiology as a medical specialty over the past four decades has changed the face of modern medicine. Developing new devices, better medications, and improved procedures is the process of innovating and research is key to innovation. Fostering research that leads to improved patient care and quality of life is essential to perpetuating the future of this innovative specialty and is the mission of this organization. Society of Interventional Radiology (SIR) Foundation is dedicated to fostering research in IR for the purposes of advancing scientific knowledge, increasing the number of skilled investigators and developing innovative therapies that lead to improved patient care and quality of life. SIR Foundation is a 501 (c)(3) charitable organization. Our work is not funded through SIR or SIR membership dues.

Successful applications for this opportunity can involve a collaborator(s) outside of IR. Co- or Multi-PIs are encouraged. Costs incurred by respondents for the preparation of a proposal and the negotiation of contract are not reimbursable. SIR Foundation is not bound to accept any of the proposals submitted. SIR Foundation reserves the right to accept any offers of the proposal without further discussion.

Table of Contents

Part 1. Overview Information
Part 2. Full Text of Announcement
Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission Information
  Content and Form of Application Submission
  Formatting Basics
  Proposal Content
  Clinical Trial Information
  Budget and Budget Justification
Section V. Application Review Information
Section VI. Award Deliverables
Section VII. Appendices Appendix
Section II. Award Information

**Funding Instrument:** All grant applications must be submitted through apply.sirfoundation.org

**Clinical Trial?** Allowed

**Anticipated Number of Awards:** SIR Foundation will fund one relevant and quality research proposal based on the merit of each proposal and the total number of submissions during the RFP period.

**Project Budget:** Project Budget may not exceed $460,000. Facilities and Administrative Costs (F&A) or indirect costs are not allowable costs for this solicitation.

**Award Project Period:** The total project period may not exceed 4 years; a single no-cost extension request may be requested for an additional year.

**Research Scope:** SIR Foundation encourages applicants to deliver high-impact studies focused on a prospective and comparative Adenomyosis clinical trial.

Section III. Eligibility Information

1. Eligible Applicants
   - Must be an SIR member
   - Eligible candidates must be full-time faculty members at an accredited educational institution in the United States or Canada. Candidate must hold an MD, DO, or an equivalent degree.
   - Applications will be accepted from citizens of the United States or Canada or those who have permanent resident status therein. Permanent residents must submit documentation of their status. If an applicant is at an institution in the US or Canada and is on a visa, a letter from the department chair guaranteeing completion of the project will be required.
   - Collaborative funding sources (federal, academic, corporate etc.) are encouraged, including proposals that augment onto ongoing Clinical Trials.

2. Cost Sharing
   This RFP does not require cost sharing.

Section IV. Application and Submission Information

1. Content and Form of Application Submission
   It is critical that applicants follow the instructions in this guide. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
Formatting Basics

<table>
<thead>
<tr>
<th>Formatting Basics</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Paper Size:</td>
<td>Standard paper size (8 1/2” x 11”)</td>
<td></td>
</tr>
<tr>
<td>Font Size:</td>
<td>11 pt or larger&lt;br&gt;Smaller font maybe used in figures, graphs, diagrams and charts</td>
<td></td>
</tr>
<tr>
<td>Recommended Fonts:</td>
<td>Arial, Georgia, Helvetica, Palatino Linotype</td>
<td></td>
</tr>
<tr>
<td>No headers or footers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Page numbers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Margins:</td>
<td>Minimum of ½ inch margin on all sides</td>
<td></td>
</tr>
</tbody>
</table>

Proposal Component

<table>
<thead>
<tr>
<th>Section in the Application</th>
<th>Page Limits</th>
<th>Details/Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cover Letter</td>
<td>1 page maximum</td>
<td>Introduction</td>
</tr>
<tr>
<td>Project Summary</td>
<td>30 lines of text maximum</td>
<td>The Project Summary is meant to service as a succinct and accurate description of the proposed work.</td>
</tr>
<tr>
<td>Project Narrative</td>
<td>3 sentences maximum</td>
<td>Relevance of the proposed research to IR</td>
</tr>
<tr>
<td>Specific Aims</td>
<td>1 page maximum</td>
<td>Plan to describe each aim in a separate paragraph. Include a brief summary of the experimental approach and anticipated outcomes for each aim</td>
</tr>
<tr>
<td>Research Strategy</td>
<td>6-page limit &lt;br&gt;a. Significance &lt;br&gt;b. Innovation &lt;br&gt;c. Approach</td>
<td>(a) <strong>Significance</strong> - Explain the importance of the problem or critical barrier to progress in interventional radiology. Explain how the proposed project will improve scientific knowledge, technical capability, and/or clinical practice in interventional radiology or other fields. Describe how the concepts, methods, technologies, treatments, services, or</td>
</tr>
</tbody>
</table>
preventative interventions that drive interventional radiology will be changed if the proposed aims are achieved.

(b) **Innovation** - Explain how the application challenges and seeks to shift current research or clinical practice paradigms. Describe any novel theoretical concepts, approaches or methodologies, instrumentation or interventions to be developed or used, and any advantage over existing methodologies, instrumentation or interventions. Explain any refinements, improvements, or new applications of theoretical concepts, approaches or methodologies, instrumentation, or interventions.

(c) **Approach** - Describe the overall strategy, methodology, and analyses to be used to accomplish the specific aims of the project. Include how the data will be collected, analyzed, and interpreted. Discuss potential problems, alternative strategies, and benchmarks for success anticipated.

<table>
<thead>
<tr>
<th>Bibliography &amp; References Cited</th>
<th>None</th>
<th>Provide a bibliography of any references cited in the Research Plan. Each reference must include the names of all authors (in the same sequence in which they appear in the publication), the article and journal title, book title, volume number, page numbers, and year of publication. Include only</th>
</tr>
</thead>
</table>
| **Biosketch**                 | 5 pages maximum per biosketch (new NIH format) and must be completed for each key personnel | Completed for all senior/key personnel and other significant contributors.  
A. Institution and Location in reverse chronological order  
B. Personal Statement  
C. Positions and Honors  
D. Contributions to IR |
| **Current and Pending**       | No page limit | A. Active  
B. Pending  
For each category Active (A) and Pending (B) include:  
• Project Number, Source, Title of Project, Major goals of project, Period of |
Clinical Trial

Is your project a clinical study or clinical trial?

Use the following four questions to determine the difference between a clinical study and a clinical trial:

1. Does the study involve human participants?
2. Are the participants prospectively assigned to an intervention?
3. Is the study designed to evaluate the effect of the intervention on the participants?
4. Is the effect being evaluated a health-related biomedical or behavioral outcome?

Note that if the answers to the 4 questions are yes, your study meets the NIH definition of a clinical trial, even if...

- You are studying healthy participants
- Your study does not have a comparison group (e.g., placebo or control)
- Your study is only designed to assess the pharmacokinetics, safety, and/or maximum tolerated dose of an investigational drug
- Your study is utilizing a behavioral intervention
- Only one aim or sub-aim of your study meets the clinical trial definition

Studies intended solely to refine measures are not considered clinical trials.
Studies that involve secondary research with biological specimens or health information are not clinical trial.

<table>
<thead>
<tr>
<th>Clinical Trial Documents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protection of Human Subjects</td>
</tr>
<tr>
<td>Multi-site Study</td>
</tr>
<tr>
<td>Data Safety and Monitoring Plan</td>
</tr>
<tr>
<td>Structure of Study Team</td>
</tr>
<tr>
<td>Protocol Synopsis</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Approved Institutional Review Board IRB Protocol</td>
</tr>
</tbody>
</table>
### Section V. Application Review Information

#### Evaluation Criteria and Scoring

Priority scores will range from 1.0 (highest priority) to 9.0 (lowest priority) amongst the following categories:

- **Significance**: Does this study address an important problem? If the aims of the application are achieved, how will scientific knowledge or clinical practice be advanced? What will be the effect of these studies on the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

- **Approach**: Are the conceptual or clinical framework, design, methods, and analyses adequately developed, well integrated, well-reasoned, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics?

- **Innovation**: Is the project original and innovative? For example: Does the project challenge existing paradigms or clinical practice; address an innovative hypothesis or critical barrier to progress in the field? Does the project develop or employ novel concepts, approaches, methodologies, tools, or technologies for this area?

- **Investigators**: Are the investigators appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers? Does the investigative team bring complementary and integrated expertise to the project?

- **Environment**: Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed studies benefit from unique features of the scientific environment, or subject populations, or employ useful collaborative arrangements? Is there evidence of institutional support?

- **Relevance to IR**: Does the application advance the research and/or clinical interests of Interventional Radiology? Does this application offer a potentially sustainable research program that could potentially lead to future NIH funding?
Section VI. Post Award Compliance

Required Deliverables & Milestones:
- Fully Executed Contract
- IRB Approval (if needed)
- Interim Progress report
- Final Progress report
- Draft of publication or proposal for follow-on funding

<table>
<thead>
<tr>
<th>Activities</th>
<th>Milestones</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st Installment</td>
<td>Fully Executed Contract Signed</td>
</tr>
<tr>
<td>2nd Installment</td>
<td>IRB Approval</td>
</tr>
<tr>
<td>Interim Progress Report; 3rd installation</td>
<td>1 year from project start date</td>
</tr>
<tr>
<td>Final Progress Report; 4th installation</td>
<td>60 days after project end date</td>
</tr>
</tbody>
</table>

Section VII. Appendices

APPENDIX A: Budget Template
1. Budget Template

APPENDIX B: Budget Justification
1. Budget Justification